01 Aug
2022
16:30 E.S.T.

Cellectis Receives IND clearance for UCART20x22, its First in-house Manufactured Product Candidate for the Treatment of B-cell Malignancies

Read more

28 Jul
2022
16:30 E.S.T.

Cellectis to Report Second Quarter 2022 Financial Results

Read more

30 Jun
2022
05:00 E.S.T.

Cellectis Publishes Article in Nature Communications Unveiling Novel Immune-Evasive Universal Allogeneic CAR T-cells with Potential for Improved Persistence

Read more

28 Jun
2022
16:30 E.S.T.

Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D., to its Board of Directors

Read more

28 Jun
2022
16:05 E.S.T.

Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 28, 2022

Read more

23 May
2022
16:30 E.S.T.

Cellectis’ Annual Shareholders’ General Meeting to be Held on June 28, 2022

Read more

16 May
2022
08:30 E.S.T.

Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCT

Read more

12 May
2022
16:30 E.S.T.

Cellectis Provides Business Update and Reports Financial Results for First Quarter 2022

Read more

05 May
2022
16:30 E.S.T.

Cellectis to Report First Quarter 2022 Financial Results

Read more

05 May
2022
16:00 E.S.T.

Calyxt, Inc., Cellectis’ Majority-Owned Subsidiary, Reports Its First Quarter 2022 Financial Results

Read more